Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

MD has been the topic of a number of other research reports. Jefferies Financial Group lifted their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Mizuho boosted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Truist Financial boosted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, UBS Group boosted their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Pediatrix Medical Group presently has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of NYSE MD traded down $0.29 during mid-day trading on Wednesday, reaching $15.22. 655,552 shares of the company were exchanged, compared to its average volume of 868,986. The company’s 50 day moving average price is $12.38 and its 200 day moving average price is $9.77. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $1.31 billion, a PE ratio of -4.97, a PEG ratio of 2.22 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the business earned $0.29 earnings per share. Sell-side analysts forecast that Pediatrix Medical Group will post 1.25 earnings per share for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,208 shares of company stock worth $327,617. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC increased its holdings in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the period. nVerses Capital LLC purchased a new stake in shares of Pediatrix Medical Group during the second quarter worth approximately $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group in the second quarter valued at approximately $33,000. Nisa Investment Advisors LLC lifted its stake in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after acquiring an additional 1,524 shares during the last quarter. Finally, CWM LLC grew its holdings in Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after acquiring an additional 3,681 shares in the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.